Wall Street Journal  49 min ago  Comment 
Novartis said it would sell parts of its Sandoz generic-drugs business in the U.S. in a deal worth up to $1 billion, the latest move by its new chief executive to refocus the Swiss pharmaceuticals giant.
The Economic Times  7 hrs ago  Comment 
The acquisition will add approximately 300 products including projects in development as well as commercial and manufacturing capabilities in the US for Aurobindo.
GenEng News  Sep 5  Comment 
Diclofenac is one of the most widely used non-steroidal anti-inflammatory drugs (NSAID) in the world, and is commonly available without prescription, but an analysis of data from more than 6.3 million people has now linked the drug with serious...
FiercePharma  Sep 5  Comment 
Little more than a week after rejecting Gilead's CAR-T cell therapy, Yescarta, for adults with relapsed large B-cell lymphoma, England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat children and...
FiercePharma  Sep 5  Comment 
CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis.
Financial Times  Sep 4  Comment 
Novartis leukaemia therapy could be available for young people within weeks
The Hindu Business Line  Sep 3  Comment 
Jubilant Cadista Pharmaceuticals Inc is recalling over 46,000 bottles of Valsartan tablets manufactured by Jubilant Generics Ltd at its Roorkee plan
Channel News Asia  Sep 1  Comment 
Switzerland's Novartis plans to streamline its worldwide production to increase its operating profit margin despite falling prices for its drugs in the United States, its chairman was reported as saying.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki